SEC Company Response from GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Jul 8, 2019
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: July 8, 2019 · CIK: 0000109657 · Accession: 0001654954-19-008000
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232261
Letter
Blueprint
GT BIOPHARMA, INC.
310 N. Westlake Blvd., Suite 206
Westlake Village, CA 91362
July 8, 2019
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
GT Biopharma, Inc.
Registration Statement on Form S-1 (File No. 333-232261)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GT Biopharma, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-232261) and declare the Registration Statement effective as of Friday, July 12, 2019, at 4:00 p.m., Eastern time, or as soon as practicable thereafter.
Please contact the undersigned at (800) 304-9888, or Gary R. Henrie, Attorney at Law at (309) 313-5092, with any questions. Also, please notify Mr. Henrie when this request for acceleration has been granted.
Very
truly yours,
GT
Biopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm Blueprint GT BIOPHARMA, INC. 310 N. Westlake Blvd., Suite 206 Westlake Village, CA 91362 July 8, 2019 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: GT Biopharma, Inc. Registration Statement on Form S-1 (File No. 333-232261) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GT Biopharma, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-232261) and declare the Registration Statement effective as of Friday, July 12, 2019, at 4:00 p.m., Eastern time, or as soon as practicable thereafter. Please contact the undersigned at (800) 304-9888, or Gary R. Henrie, Attorney at Law at (309) 313-5092, with any questions. Also, please notify Mr. Henrie when this request for acceleration has been granted. Very truly yours, GT Biopharma, Inc. By: /s/ Steven Weldon Name: Steven Weldon Title: Chief Financial Officer cc: Gary R. Henrie, Attorney at Law